Current status and perspectives in immunotherapy for metastatic melanoma
Metrics: PDF 1058 views | HTML 2106 views | ?
Riccardo Marconcini1, Francesco Spagnolo2, Luigia Stefania Stucci3, Simone Ribero4, Elena Marra4, Francesco De Rosa5, Virginia Picasso2, Lorenza Di Guardo6, Carolina Cimminiello6, Stefano Cavalieri6, Laura Orgiano7, Enrica Tanda2, Laura Spano2, Alfredo Falcone1 and Paola Queirolo2 for the Italian Melanoma Intergroup (IMI)
1Unit of Medical Oncology 2, Azienda Ospedaliera-Universitaria Pisana, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Italy
2Department of Medical Oncology, IRCCS AOU San Martino-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
3Medical Oncology Unit, Department of Biomedical Sciences and Clinical Oncology, University of Bari, Bari, Italy
4Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy
5Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST IRCCS, Meldola, Italy
6Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
7AOU Cagliari, Department of Medical Oncology, University of Cagliari, Cagliari, Italy
Riccardo Marconcini, email: firstname.lastname@example.org
Keywords: melanoma; immunotherapy; ipilimumab; pembrolizumab; nivolumab
Received: April 23, 2017 Accepted: November 03, 2017 Published: January 03, 2018
Metastatic melanoma was the first malignancy in which immune checkpoint inhibitors demonstrated their successful efficacy. Currently, the knowledge on the interaction between the immune system and malignant disease is steadily increasing and new drugs and therapeutic strategies are overlooking in the clinical scenario. To provide a comprehensive overview of immune modulating drugs currently available in the treatment of melanoma as well as to discuss of possible future strategies in the metastatic melanoma setting, the present review aims at analyzing controversial aspects about the optimal immunomodulating treatment sequences, the search for biomarkers of efficacy of immunocheckpoint inhibitors, and innovative combinations of drugs currently under investigation.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.